Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
4.040
+0.010 (0.25%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Checkpoint Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Checkpoint Therapeutics stock have an average target of 4.33, with a low estimate of 4.10 and a high estimate of 4.80. The average target predicts an increase of 7.18% from the current stock price of 4.04.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Checkpoint Therapeutics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $4.1 | Strong Buy → Hold | Downgrades | $4.1 | +1.49% | Mar 11, 2025 |
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $7 → $4.1 | Strong Buy → Hold | Downgrades | $7 → $4.1 | +1.49% | Mar 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 → $4.8 | Strong Buy | Maintains | $9 → $4.8 | +18.81% | Mar 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +122.77% | Jan 13, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +73.27% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
13.94K
from 103.00K
Decreased by -86.46%
Revenue Next Year
41.94M
from 13.94K
Increased by 300,658.78%
EPS This Year
-0.93
from -1.87
EPS Next Year
-0.17
from -0.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 43,050 | 76.5M | 195.0M | |||
| Avg | 13,943 | 41.9M | 189.4M | |||
| Low | n/a | 9.2M | 182.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -58.2% | 548,324.3% | 365.0% | |||
| Avg | -86.5% | 300,658.8% | 351.7% | |||
| Low | - | 65,967.1% | 334.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.87 | 0.47 | 0.97 | |||
| Avg | -0.93 | -0.17 | 0.94 | |||
| Low | -0.94 | -0.76 | 0.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.